Your browser doesn't support javascript.
loading
The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia.
Beekman, Renée; Chapaprieta, Vicente; Russiñol, Núria; Vilarrasa-Blasi, Roser; Verdaguer-Dot, Núria; Martens, Joost H A; Duran-Ferrer, Martí; Kulis, Marta; Serra, François; Javierre, Biola M; Wingett, Steven W; Clot, Guillem; Queirós, Ana C; Castellano, Giancarlo; Blanc, Julie; Gut, Marta; Merkel, Angelika; Heath, Simon; Vlasova, Anna; Ullrich, Sebastian; Palumbo, Emilio; Enjuanes, Anna; Martín-García, David; Beà, Sílvia; Pinyol, Magda; Aymerich, Marta; Royo, Romina; Puiggros, Montserrat; Torrents, David; Datta, Avik; Lowy, Ernesto; Kostadima, Myrto; Roller, Masa; Clarke, Laura; Flicek, Paul; Agirre, Xabier; Prosper, Felipe; Baumann, Tycho; Delgado, Julio; López-Guillermo, Armando; Fraser, Peter; Yaspo, Marie-Laure; Guigó, Roderic; Siebert, Reiner; Martí-Renom, Marc A; Puente, Xose S; López-Otín, Carlos; Gut, Ivo; Stunnenberg, Hendrik G; Campo, Elias.
Afiliación
  • Beekman R; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Chapaprieta V; Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona, Barcelona, Spain.
  • Russiñol N; Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
  • Vilarrasa-Blasi R; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Verdaguer-Dot N; Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
  • Martens JHA; Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
  • Duran-Ferrer M; Molecular Biology, NCMLS, FNWI, Radboud University, Nijmegen, The Netherlands.
  • Kulis M; Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
  • Serra F; Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain.
  • Javierre BM; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Wingett SW; Structural Genomics Group, CNAG-CRG, The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Clot G; Gene Regulation, Stem Cells and Cancer Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Queirós AC; Nuclear Dynamics Program, Babraham Institute, Babraham Research Campus, Cambridge, UK.
  • Castellano G; Nuclear Dynamics Program, Babraham Institute, Babraham Research Campus, Cambridge, UK.
  • Blanc J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Gut M; Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona, Barcelona, Spain.
  • Merkel A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Heath S; Core Biología Molecular, CDB, Hospital Clínic, Barcelona, Spain.
  • Vlasova A; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Ullrich S; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Palumbo E; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Enjuanes A; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Martín-García D; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Beà S; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Pinyol M; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Aymerich M; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Royo R; Bioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology and UPF, Barcelona, Spain.
  • Puiggros M; Bioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology and UPF, Barcelona, Spain.
  • Torrents D; Bioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology and UPF, Barcelona, Spain.
  • Datta A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Lowy E; Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona, Barcelona, Spain.
  • Kostadima M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Roller M; Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona, Barcelona, Spain.
  • Clarke L; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Flicek P; Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona, Barcelona, Spain.
  • Agirre X; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Prosper F; Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona, Barcelona, Spain.
  • Baumann T; Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona, Barcelona, Spain.
  • Delgado J; Unitat de Hematología, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
  • López-Guillermo A; Programa Conjunto de Biología Computacional, Barcelona Supercomputing Center (BSC), Institut de Recerca Biomèdica (IRB), Spanish National Bioinformatics Institute, Universitat de Barcelona, Barcelona, Spain.
  • Fraser P; Programa Conjunto de Biología Computacional, Barcelona Supercomputing Center (BSC), Institut de Recerca Biomèdica (IRB), Spanish National Bioinformatics Institute, Universitat de Barcelona, Barcelona, Spain.
  • Yaspo ML; Programa Conjunto de Biología Computacional, Barcelona Supercomputing Center (BSC), Institut de Recerca Biomèdica (IRB), Spanish National Bioinformatics Institute, Universitat de Barcelona, Barcelona, Spain.
  • Guigó R; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
  • Siebert R; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, UK.
  • Martí-Renom MA; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, UK.
  • Puente XS; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, UK.
  • López-Otín C; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, UK.
  • Gut I; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, UK.
  • Stunnenberg HG; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, UK.
  • Campo E; Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona, Barcelona, Spain.
Nat Med ; 24(6): 868-880, 2018 06.
Article en En | MEDLINE | ID: mdl-29785028
Chronic lymphocytic leukemia (CLL) is a frequent hematological neoplasm in which underlying epigenetic alterations are only partially understood. Here, we analyze the reference epigenome of seven primary CLLs and the regulatory chromatin landscape of 107 primary cases in the context of normal B cell differentiation. We identify that the CLL chromatin landscape is largely influenced by distinct dynamics during normal B cell maturation. Beyond this, we define extensive catalogues of regulatory elements de novo reprogrammed in CLL as a whole and in its major clinico-biological subtypes classified by IGHV somatic hypermutation levels. We uncover that IGHV-unmutated CLLs harbor more active and open chromatin than IGHV-mutated cases. Furthermore, we show that de novo active regions in CLL are enriched for NFAT, FOX and TCF/LEF transcription factor family binding sites. Although most genetic alterations are not associated with consistent epigenetic profiles, CLLs with MYD88 mutations and trisomy 12 show distinct chromatin configurations. Furthermore, we observe that non-coding mutations in IGHV-mutated CLLs are enriched in H3K27ac-associated regulatory elements outside accessible chromatin. Overall, this study provides an integrative portrait of the CLL epigenome, identifies extensive networks of altered regulatory elements and sheds light on the relationship between the genetic and epigenetic architecture of the disease.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cromatina / Leucemia Linfocítica Crónica de Células B / Epigenómica Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cromatina / Leucemia Linfocítica Crónica de Células B / Epigenómica Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: España